Tobacco-Free Kids Files Election Complaint Against Big Tobacco

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 9
Volume 7
Issue 9

WASHINGTON--A complaint filed with the Federal Election Commission (FEC) accuses five major tobacco companies of violating federal law by indicating they would pay for advertising to support the re-election bids of senators who voted against comprehensive tobacco legislation.

WASHINGTON--A complaint filed with the Federal Election Commission (FEC) accuses five major tobacco companies of violating federal law by indicating they would pay for advertising to support the re-election bids of senators who voted against comprehensive tobacco legislation.

The complaint, filed by the Campaign for Tobacco-Free Kids, contends that shortly before a key vote on the McCain bill, Sen. Mitch McConnell (R-Ky) told fellow Republicans that "if they voted to kill the tobacco bill, the major tobacco manufactures were promising to mount a television ad campaign to support those who voted against the bill." The complaint contends that this promise violates federal laws that forbid corporations from making contributions or expenditures in federal elections.

Articles in this issue
Intensive Effort Required to Develop a Breast Cancer Risk Assessment Clinic
NCI Readies Its Cancer Genetics Network for Collaborative Studies
Payer Relationships Key to Transplant Revenues
Taking Family Cancer History May Release Emotions
Ovarian Cortical Tissue Is Cryopreserved for Future Fertility
Advice Offered for Daughters of Women With Breast Cancer
WHO to List Exchange Programs in Cancer Ed
Women’s Groups Ask Congress for Global Tobacco Controls
Brain Tumor Patients Urged to ‘Seize Control’ of Their Seizures
UCSF Breaks Ground for Its New Clinical Cancer Building
Preventive Effects of Tamoxifen Vary With HER2 Level
NIH Expert Dispels Myths About Genetic Counseling
Advanced Colorectal Cancer Patients May Prefer Raltitrexed
FDG-PET Finds Residual, Recurrent Hodgkin's Disease
Ceprate Gets FDA Nod for Peripheral Blood Stem Cell Selection
Recent Videos
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Genetic backgrounds and ancestry may hold clues for better understanding pancreatic cancer, which may subsequently mitigate different disparities.
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
Thomas Hope, MD, believes that an NRC initiative to update infiltration guidelines may organically address concerns that H.R. 2541 outlines.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
4 experts are featured in this series.
4 experts are featured in this series.
Thomas Hope, MD, had not observed an adverse effect attributable to an infiltration across more than a decade of administering nuclear agents at UCSF.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
Two experts are featured in this series.
Related Content
As Late-Career Oncologists Retire, Who Will Fill the Geographic Gaps?

As Late-Career Oncologists Retire, Who Will Fill the Geographic Gaps?

Ariana Pelosci
November 28th 2025
Article

A recent study found that the number of practicing oncologists is declining as the US population ages and cancer diagnoses continue to increase.

Decision-Making Capacity: The Ethical Core of Patient-Centered Oncology

Decision-Making Capacity: The Ethical Core of Patient-Centered Oncology

Daniel C. McFarland, DO;Louis P. Voigt, MD;Yesne Alici, MD
November 24th 2025
Podcast

Daniel C. McFarland, DO, is joined by Louis P. Voigt, MD, and Yesne Alici, MD, who focused on decision-making capacity and patient-centered care.

Tisa-Cel Maintains Efficacy at 5-Year Analysis in R/R LBCL

Tisa-Cel Maintains Efficacy at 5-Year Analysis in R/R LBCL

Ariana Pelosci
November 26th 2025
Article

ORR, DOR, PFS, and OS showed continued improvement for patients with relapsed/refractory LBCL receiving tisagenlecleucel.

Michael Barish, PhD, discusses a novel cellular therapy for patients with glioblastoma that harnesses chlorotoxin, a peptide found in scorpion venom.

How Can Chlorotoxin-Directed CAR T-Cell Therapy Impact Glioblastoma Care?

Michael Barish, PhD
November 17th 2025
Podcast

Michael Barish, PhD, discusses a novel cellular therapy for patients with glioblastoma that harnesses chlorotoxin, a peptide found in scorpion venom.

177Lu/SBRT Improves PFS in Oligorecurrent Hormone-Sensitive Prostate Cancer

177Lu/SBRT Improves PFS in Oligorecurrent Hormone-Sensitive Prostate Cancer

Ariana Pelosci
November 26th 2025
Article

In the 177Lu plus SBRT arm, the median PFS was 17.6 months vs 7.4 months in the SBRT alone arm for patients with oligorecurrent HSPC.

Investigators are currently assessing the safety and preliminary activity of AVZO-103 among patients with advanced solid tumors in a phase 1/2 trial.

Novel Bispecific ADC Earns FDA Fast Track Status in Urothelial Cancer

Russ Conroy
November 25th 2025
Article

Investigators are currently assessing the safety and preliminary activity of AVZO-103 among patients with advanced solid tumors in a phase 1/2 trial.